Clinical trial
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
The purpose of this study is to assess the safety and tolerability of ABBV-951 in subjects with Parkinson's disease (PD).
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 130 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
Actual Study Start Date: April 29, 2019
Estimated Primary Completion Date: April 23, 2021
Estimated Study Completion Date: June 26, 2021
Arm:
- Experimental: ABBV-951
| Category | Value |
|---|---|
| Date last updated at source | 2019-09-23 |
| Study type(s) | Interventional |
| Expected enrolment | 130 |
| Study start date | 2019-04-29 |
| Estimated primary completion date | 2021-04-23 |